TWI906448B - Kras g12c抑制劑在治療癌症中之用途 - Google Patents

Kras g12c抑制劑在治療癌症中之用途

Info

Publication number
TWI906448B
TWI906448B TW111100657A TW111100657A TWI906448B TW I906448 B TWI906448 B TW I906448B TW 111100657 A TW111100657 A TW 111100657A TW 111100657 A TW111100657 A TW 111100657A TW I906448 B TWI906448 B TW I906448B
Authority
TW
Taiwan
Prior art keywords
subject
kras
mutation
formula
stk11
Prior art date
Application number
TW111100657A
Other languages
English (en)
Chinese (zh)
Other versions
TW202241442A (zh
Inventor
安吉斯 李 央
哈比 海納瑞
格塔力 葛恰納瑞
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202241442A publication Critical patent/TW202241442A/zh
Application granted granted Critical
Publication of TWI906448B publication Critical patent/TWI906448B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111100657A 2021-01-08 2022-01-07 Kras g12c抑制劑在治療癌症中之用途 TWI906448B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163135449P 2021-01-08 2021-01-08
US63/135,449 2021-01-08
US202163189625P 2021-05-17 2021-05-17
US63/189,625 2021-05-17

Publications (2)

Publication Number Publication Date
TW202241442A TW202241442A (zh) 2022-11-01
TWI906448B true TWI906448B (zh) 2025-12-01

Family

ID=80222156

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111100657A TWI906448B (zh) 2021-01-08 2022-01-07 Kras g12c抑制劑在治療癌症中之用途

Country Status (8)

Country Link
US (1) US20240091230A1 (cg-RX-API-DMAC7.html)
EP (2) EP4274579A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502446A (cg-RX-API-DMAC7.html)
AU (1) AU2022205969A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206523A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023007918A (cg-RX-API-DMAC7.html)
TW (1) TWI906448B (cg-RX-API-DMAC7.html)
WO (1) WO2022150628A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
EP3738593A1 (en) * 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 HONG DAVID S. ET AL KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors THE NEW ENGLAND JOURNAL OF MEDICINE vol. 383, no. 13 2020/09/24 1207-1217

Also Published As

Publication number Publication date
MX2023007918A (es) 2023-07-13
WO2022150628A1 (en) 2022-07-14
EP4650006A3 (en) 2026-01-14
EP4274579A1 (en) 2023-11-15
US20240091230A1 (en) 2024-03-21
AU2022205969A1 (en) 2023-07-06
EP4650006A2 (en) 2025-11-19
JP2024502446A (ja) 2024-01-19
AU2022205969A9 (en) 2024-02-08
TW202241442A (zh) 2022-11-01
CA3206523A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
US20240091230A1 (en) Use of kras g12c inhibitor in treating cancers
JP2023145689A (ja) Her2陽性がんの処置
EP4340842B1 (en) Sotorasib for use in the treatment of cancer
US20260069593A1 (en) Methods for treating cancer
TW202302112A (zh) 索托拉西布給藥方案
CN105848678A (zh) 核酸生物标志物及其用途
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
EP3908282B1 (en) Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors
JP2026053570A (ja) Kras g12c変異を含む癌を治療するためのソトラシブ及びegfr抗体
Johnson et al. 8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
US20230321102A1 (en) TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
HK40102675A (en) Sotorasib dosing regimen
WO2024015360A1 (en) Methods of treating cancer
HK40126893A (en) Dosage regimen for sotorasib/carboplatin/pemetrexed in cancer treatment
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
HK40111140A (en) Sotorasib and an egfr antibody for treating cancer comprising a kras g12c mutation
EA051386B1 (ru) Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c
CN116981462A (zh) 索托拉西布给药方案
KR20250170664A (ko) 암 치료에서 소토라십/카보플라틴/페메트렉시드에 대한 투여량 양생법
Langer Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.